Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 9c; Approves $75M Stock Buyback Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eagle Pharmaceuticals (EGRX) Announces Positive Results from Ryanodex NDA Meeting w/ FDA
August 9, 2016 6:46 AM EDTEagle Pharmaceuticals (Nasdaq: EGRX) announced that the U.S. Food and Drug Administration ("FDA") has determined that no additional human safety and efficacy data is required for the submission of Eagles New Drug Application (NDA) for Ryanodex® for the treatment of exertional heat stroke (EHS), an investigational new indication for the product, further confirming that a hybrid development program comprised of clinical data from EHS patients and preclinical data from animal studies constitutes an adequate regulatory pathway for the NDA submission.
Eagle has also reduced its future Ryanodex royalty obligations to its licensing... More
